Healthcare
Live Price
Offline$7.80
-1.27% today
1Y Change
-15.27%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
REGENXBIO Inc. (RGNX) is a Healthcare stock with a market cap of $470.00M and listed on NASDAQ. The stock last traded around $7.80 and down 15.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +104.5%, EPS growth of +18.1%, a dividend yield of 0.0%. What stands out right now is revenue +104.5%, EPS +18.1%, free cash flow +28.0% with operating margin -94.6% and ROIC -42.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RGNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGNX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGNX Max Drawdown
-64.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGNX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$470.3M
+317.3% YoY
FY Net Income
$127.8M
+145.6% YoY
Free Cash Flow
$134.7M
+156.5% YoY
Revenue Growth
+104.5%
EPS Growth
+18.1%
Gross Margin
52.9%
Net Margin
-113.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 170M | 83M | 90M | 113M | 470M |
| Gross Profit | 150M | 50M | 53M | 58M | 419M |
| Operating Income | -161M | -233M | -268M | -263M | 160M |
| EBITDA | -146M | -198M | -239M | -244M | 170M |
| Net Income | -194M | -227M | -263M | -280M | 128M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34M | 58M | 35M | 97M | 345M |
| Total Assets | 453M | 466M | 574M | 833M | 1.1B |
| Total Liabilities | 350M | 206M | 262M | 317M | 350M |
| Shareholder Equity | 103M | 260M | 312M | 516M | 764M |
| Total Debt | 261M | 82M | 89M | 95M | 87M |
| Net Debt | 226M | 25M | 55M | -2M | -259M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
219M
+205.5% YoY
Capital Expenditures
84M
-174.0% YoY
Free Cash Flow
135M
+156.5% YoY
Key ratios
Gross Margin
52.9%
Operating Margin
-94.6%
Net Margin
-113.8%
ROE
-103.1%
Debt / Equity
2.54x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.